Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,201.60 today based on a ...

We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at ...

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as ...

Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to ...